-
-
-
-
-
-
-
atai Life Sciences (ATAI) Misses Q2 EPS by 2c
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Reports In-Line Q3 EPS
-
-
-
-
-
-
-
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
-
-
-
-
-
-
-
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
-
-
-
-
-
-
-
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
-
-
-
-
-
-
-
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
-
-
-
-
-
-
-
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Trea
-
1,206,285 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

